

IELSG

INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP

TRIALS COORDINATION CENTRE: ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND

OSPEDALE SAN GIOVANNI CH-6500 BELLINZONA - SWITZERLAND

E. ZUCCA, A. CONCONI, S. GRISANTI, F. CAVALLI / C. MORININI, M. TROVESI

PHONE ++41 91 820 91 11 - FAX ++41 91 820 91 82 - E-MAIL ielsg@ticino.com

NEWSLETTER 9

Bellinzona, November 2001

Dear Colleagues,

Following the 4th IELSG workshop of May 2001, consistent efforts have been made by several centres worldwide to realise and activate the new protocols of study.

The present Newsletter is intended to update all members about the state of these new and ongoing protocols.

Due to the increasing number of participating institutions, data collection from each study will be centralised at the IELSG Trials Coordination Centre, which in turn will send them to the single trial Chairmen.

All protocols and forms will be provided upon request to ielsg@ticino.com.

IELSG 14: RETROSPECTIVE EVALUATION OF PRIMARY BONE LYMPHOMA

1. The protocol is officially open.
2. Forms are intended to be filled and sent as attached documents by e-mail. Histological reports must be faxed or sent by mail as usual.
3. This study provides for a pathological review. Please look at the protocol for details.
4. Chairperson: David Christie, Tugun, Australia, Co-Chairpersons: Mary Gospodarowicz, Toronto, Canada; Bertrand Coiffier, Lyon, France; Giovanni Martinelli, Milan, Italy.

IELSG 15: RETROSPECTIVE EVALUATION OF PRIMARY BREAST LYMPHOMA

1. The protocol is officially open
2. Filled forms must be sent to IELSG Central Office (at the address above) by mail
3. This study provides for a pathological review to be done. Please look at the protocol for details
4. Chairpersons: Giovanni Martinelli, Milan, Italy and Gail Ryan, Melbourne, Australia.

IELSG 16: RT-PCR DETECTION OF THE t(11;18) TRANSLOCATION AS A PREDICTOR OF OUTCOME IN EXTRANODAL MARGINAL LYMPHOMA OF MALT TYPE

1. The study is officially open.
2. Pathological material to be analysed should be received by dr. Claudio Realini, Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland, Ospedale La Carità, CH-6600 Locarno. Look at the protocol for details.
3. Chairmen: F. Bertoni, London, UK; E. Zucca, Bellinzona, Switzerland

REMEMBER THE ONGOING PROSPECTIVE CLINICAL STUDIES

Please, do not forget that the following prospective clinical studies are open for patients' registration in order to increase accrual.

IELSG 4: PROSPECTIVE RANDOMIZED TRIAL OF CHEMOTHERAPY VS CHEMOTHERAPY PLUS IRRADIATION IN DIFFUSE LARGE-CELL GASTRIC LYMPHOMA (Chairman: G. Martinelli, Milano, Italy) Please contact: <katia.deluzio@ieo.it>

IELSG 10: A PHASE II STUDY OF CHOP, WITH INTRATHECAL METHOTREXATE FOLLOWED BY RADIOTHERAPY, IN PATIENTS WITH PRIMARY TESTICULAR NON-HODGKIN'S LYMPHOMA (Chairman: A. Sarris, Houston, USA) Please contact: <ielsg@ticino.com> or <omesina@mail.manderson.org>

AMENDMENT TO THE IELSG 10 PROTOCOL

Treatment plan has been modified by the addition of Mabthera to standard dose CHOP. Mabthera will be administered at the beginning of each of the 6-8 scheduled cycles of CT. For the European countries where Mabthera is not reimbursed by local insurances for this indication, an agreement has been arranged with Roche International for drug supply at no further charge. The local Roche Company should contact directly Roche International at the following e-mail address: <michelle.rashford@roche.com>

IELSG AGENDA

The next IELSG meeting will be held in Lugano, Switzerland during the 8th International Conference on Malignant Lymphomas, on Saturday, June 15, 2002 at the Palazzo dei Congressi (approximately from 1:00 pm to 5:00 pm)

Growing activities of IELSG and its worldwide involvement caused the staff to be reinforced by 2 new entries: Salvatore Grisanti, MD and Monica Trovesi, Scientific Secretary.

To you all the best wishes for a fruitful work.

Yours sincerely

E. Zucca, S. Grisanti, F. Cavalli, C. Morinini, M. Trovesi